No Data
No Data
Foghorn Therapeutics Unveils Clinical Pipeline Progress
Express News | Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors
Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
Express News | Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Press Release: Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
loading...
loading...